Adipose Tissue
Definition
A specialized connective tissue responsible for storing energy in the form of triglycerides and functioning as an endocrine organ that secretes hormones and signaling molecules (adipokines) involved in metabolism, inflammation, and insulin sensitivity.
Adipose Tissue
Adipose tissue is a highly dynamic connective tissue that serves as the body’s primary energy reservoir, storing calories in the form of triglycerides within specialized cells known as adipocytes. Beyond its energy storage function, adipose tissue is now recognized as a major endocrine organ capable of secreting a wide array of bioactive molecules collectively termed adipokines. These include leptin, adiponectin, resistin, and various inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Through these secreted factors, adipose tissue plays a central role in regulating energy balance, glucose metabolism, lipid homeostasis, and systemic inflammation.
Two major types of adipose tissue exist in humans: white adipose tissue (WAT) and brown adipose tissue (BAT). White adipose tissue is the predominant form in adults and is primarily responsible for energy storage and adipokine secretion. Brown adipose tissue, in contrast, is thermogenically active and dissipates energy as heat through the action of uncoupling protein 1 (UCP1). A third category, beige or brite adipocytes, can arise within white adipose depots in response to cold exposure or pharmacological stimulation and exhibit thermogenic properties similar to brown fat. The balance between energy storage in WAT and energy dissipation in BAT and beige fat is of significant interest in obesity research.
Clinical Relevance to Retatrutide
Excessive expansion of adipose tissue, particularly visceral adipose tissue surrounding abdominal organs, is a hallmark of obesity and is strongly associated with insulin resistance, type 2 diabetes, and cardiovascular disease. Retatrutide, as a triple agonist targeting GLP-1, GIP, and glucagon receptors, has demonstrated substantial reductions in body weight in clinical trials, reflecting significant loss of adipose tissue mass. The glucagon receptor agonism component of retatrutide is hypothesized to promote lipolysis and increase energy expenditure, potentially enhancing fat loss beyond what is achieved with GLP-1 receptor agonism alone. Reductions in visceral and ectopic fat deposits may underlie many of the metabolic improvements observed with retatrutide therapy, including enhanced insulin sensitivity and reduced hepatic steatosis.